TrialMedical oncology (Northwood, London, England)2019

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).

Naoki Nagata et al.PubMed ↗Publisher ↗

No numbers read from the abstract.